Strategic Initiative

Slingshot members are tracking this corporate initiative:

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer Antibody-Drug Conjugates and XMT-1522

Source Link:: http://www.takeda.com/news/2016/20160203_7285.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

TKD.F

100%

MRSN

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details -Takeda obtains rights to Mersana’s XMT-1522 outside U.S. and Canada
-Takeda to create additional Fleximer ADCs; Mersana to have a co-development option
-Mersana to receive $40 million upfront, $20 million upon IND clearance and up to $20 million in equity investment

http://www.takeda.co...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Feb 03, 2016

Projected Implementation:

Q1, 2018

Relevance Tracked Until:

Q4, 2018

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Partnership, Fleximer Antibody-drug Conjugates, Xmt-1522